# CBB-120

Source: https://onco.cc/drugs/cbb-120/  
OnCo record `cbb-120` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CBB-120 is an experimental drug designed to carry chemotherapy to cancer cells. Its published evidence is from laboratory and animal studies.

## Summary

AACR-NCI-EORTC 2025 abstract A124 describes CBB-120 with EGCit linkers and TOP1/ATR inhibitor payloads. Evidence includes cell assays, xenografts and cynomolgus-monkey toxicology. Tumor regressions and comparisons with single-payload ADCs were in models, not a randomized clinical comparison. On-target skin toxicity was observed in monkeys; clinical benefit and safety remain unestablished.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-10-06
- Tags: evidence:preclinical
- Modality: ADC
- Mechanism: Site-specific, Fc-silenced anti-TROP2 ADC delivering a TOP1 inhibitor and an ATR inhibitor to combine DNA damage with inhibition of its repair.
- Payload: TOP1 inhibitor plus ATR inhibitor

## Sources

- Publisher abstract: https://doi.org/10.1158/1535-7163.targ-25-a124

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Dual-payload ADC](https://onco.cc/technologies/dual-payload-adc/)
- targets: [TROP2](https://onco.cc/targets/trop2/)

---
JSON: https://onco.cc/api/v1/entities/cbb-120.json